John P Rossiter
Overview
Explore the profile of John P Rossiter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
964
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu T, Rossiter J, Houlden R, Awad S
AACE Clin Case Rep
. 2022 Aug;
8(4):166-170.
PMID: 35959088
Objective: Pituitary corticotroph macroadenomas, which account for 7% to 23% of corticotroph adenomas, rarely present with apoplexy. This report aimed to describe a patient with a sparsely granulated corticotroph tumor...
2.
Xu M, Orr C, LeBrun D, Rossiter J
EJHaem
. 2022 Jul;
2(3):672-673.
PMID: 35844720
No abstract available.
3.
Basseri S, Rossiter J, Wallace M, Islam O, Tampieri D, Kwan B
Can J Neurol Sci
. 2020 Jul;
48(1):116-117.
PMID: 32660652
A previously healthy 48-year-old female presented to the emergency department with a 2-week history of low back pain, progressive lower extremities weakness, and right leg numbness. There were no bowel...
4.
Durafourt B, Rossiter J, Baharnoori M
Can J Neurol Sci
. 2020 Mar;
47(5):727-730.
PMID: 32213219
No abstract available.
5.
LaPointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, et al.
Invest New Drugs
. 2019 Nov;
38(4):1137-1144.
PMID: 31707687
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM) development and progression, and in resistance to anti-cancer therapies. Inhibition of the PI3K pathway has been shown to...
6.
Perry J, Laperriere N, OCallaghan C, Brandes A, Menten J, Phillips C, et al.
N Engl J Med
. 2017 Mar;
376(11):1027-1037.
PMID: 28296618
Background: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added...
7.
Baumert B, Hegi M, van den Bent M, von Deimling A, Gorlia T, Hoang-Xuan K, et al.
Lancet Oncol
. 2016 Oct;
17(11):1521-1532.
PMID: 27686946
Background: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide...
8.
Turashvili G, Varma S, SenGupta S, Rossiter J
Brain Pathol
. 2016 Sep;
26(5):677-8.
PMID: 27667802
No abstract available.
9.
10.
Trebuss K, Buttemer S, Wilkinson J, Xu J, Rossiter J, Moore K
Can J Infect Dis Med Microbiol
. 2016 Jul;
2016:2478924.
PMID: 27366159
Tumour necrosis factor alpha inhibitors, such as infliximab, and other biologic agents are associated with increased risk of opportunistic infection, including tuberculosis. Tuberculosis infections associated with infliximab tend to present...